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Background: Mutations in the TP53 (Tumour Protein 53) gene can lead to expression of mutant p53 proteins that
accumulate in cancer cells and can induce circulating p53 antibodies in cancer patients. Our aim was to evaluate
the presence and prognostic role of these antibodies in lung cancer patients and to investigate whether they were
related to p53 expression or TP53 mutations in tumour tissues.
Methods: A total of 201 lung cancer patients were evaluated for p53 antibodies by ELISA (Enzyme-Linked
Immunosorbent Assay) and control was obtained from 54 patients with non-malignant disorders; p53 expression
was evaluated in 131 of the lung cancer patients by immunohistochemistry and TP53 mutations were then
investigated in 53 tumours positively staining for p53 and in 12 tumours without p53 overexpression, whose
DNA was available for direct sequencing.
Results: Our results show that 20.4% of cancer patients have positive levels of p53 antibodies, while none of the
controls resulted positive. High levels of p53 expression are detected in 57.3% of cases and a significant correlation
between serum p53 antibodies and high levels of p53 expression in the corresponding tumours is observed. In
non-small cell lung cancer, p53 antibodies are significantly associated with poorly differentiated tumours;
furthermore, high levels of p53 expression significantly correlated with squamous cell carcinoma and tumours with
highest grade. Survival time of non-small cell lung cancer patients low/negative for serum p53 antibodies was
significantly longer compared to patients with positive levels (p = 0.049); in particular, patients with squamous
cell carcinoma, but not adenocarcinoma, low/negative for these antibodies show a significant better survival
compared to serum-positive patients (p = 0.044).
Conclusions: In our study, detection of serum p53 antibodies in non-small cell lung cancer patients has been
shown to be useful in identifying subsets of patients with poor prognosis. A significant correlation between the
presence of serum p53 antibodies in lung cancer patients and p53 overexpression in the corresponding tumours was
also observed. We did not find a significant correlation between levels of serum p53 antibodies and TP53 mutations
in the corresponding tumours.
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Lung cancer represents the most common cancer in de-
veloped countries and the leading cause of tumour death
in the world [1]. Usually, lung cancer does not show
symptoms in early stages and most patients are diag-
nosed in advanced stages, when they are inoperable;* Correspondence: mattioni@ifo.it
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biomarkers may be of remarkable clinical importance.
The tumour suppressor p53 is involved in cell growth
regulation, cell cycle progression, DNA repair and apop-
tosis; mutations in the TP53 gene, the most common
genetic alterations in human cancers, can lead to pro-
duction of dysfunctional p53 proteins that may allow the
survival of genetically unstable cells that can turn into
malignant cells [2]. Mutant p53 proteins show a longer
half-life than wild-type p53, resulting in accumulation inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Lung cancer patients Controls
Age (years)
≤60 47 (23.4%) 27 (50.0%)
>60 154 (76.6%) 27 (50.0%)
Total 201 54
Sex
Male 157 (78.1%) 27 (50.0%)





Squamous cell carcinoma 70 (34.8%)
Bronchioloalveolar carcinoma 6 (3.0%)
Large cell carcinoma 5 (2.5%)
Anaplastic carcinoma 19 (9.4%)
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culating p53 antibodies (p53Abs) in patients bearing
various types of cancer, including lung cancer, presum-
ably because the altered conformation of p53 produced
by mutations may trigger an autoimmune response once
the protein has been released from tumour cells [3].
There is a close correlation between serum p53Abs and
p53 overexpression in tumour tissues, thus p53Abs can
be considered as markers for the presence of TP53 mu-
tations [4]. In lung cancer, TP53 mutations arise early
and p53 overexpression was detected in pre-neoplastic
lesions, such as bronchial dysplasia. In addition, serum
p53Abs were found in heavy smokers several months
before the diagnosis of lung cancer [5].
In a systematic review of published studies, the fre-
quency of serum p53Abs in most of cancer patients
resulted higher than in healthy and benign controls;
therefore, detection of serum p53Abs may have potential
diagnostic value for different types of cancer, including
lung cancer [6]. However, another meta-analysis sug-
gested that the low sensitivity of serum p53Abs limited
their use in the screening of lung cancer [7]. A combin-
ation of serum p53Abs with other conventional markers
increased the sensitivity and specificity for detecting
lung cancer [8]. Serum p53Abs may be useful also for
predicting chemosensitivity in lung cancer: actually,
serum p53Ab levels significantly decreased after neoad-
juvant chemotherapy and low levels of serum p53Abs
before neoadjuvant chemotherapy correlated with high
objective chemoresponse rate [9].
Prognostic implications in lung cancer of p53Abs are
controversial: in non-small cell lung cancer (NSCLC),
p53Abs were found to be related to short survival,
but some studies showed the absence of correlation;
in small cell lung cancer (SCLC), either a better sur-
vival in patients with high levels of p53Abs or a
shorter survival in p53Ab positive patients with lim-
ited disease, as well as lack of prognostic relevance
have been observed [10]. The reported differences in
prognostic correlations may be partially due to the
different sensitivity and reactivity of the methods
employed or to the peculiar characteristics of each
investigated population.
Furthermore, as results of most studies are limited to
the prognostic role of serum p53Abs, the aim of our
work was not only to determine serum p53Abs in lung
cancer patients and evaluate their prognostic role, but
also to examine whether these antibodies were associ-
ated with p53 protein expression or mutations in corre-
sponding tumour tissues, as p53 overexpression is
believed to be an important trigger for the production of
serum p53Abs. For these purposes, we simultaneously
determined in lung cancer patients serum p53Abs by
a highly specific ELISA, p53 protein expression byimmunohistochemistry (IHC) and TP53 gene mutations




A total of 255 patients were evaluated (Table 1). Of these
patients, 201 had histologically diagnosed primary lung
cancer: 13 patients had SCLC and 188 patients had
NSCLC. Control was obtained from 54 patients with be-
nign lung diseases or disorders not related to respiratory
diseases. All patients were enrolled at the Thoracic Surgery
Unit of the Regina Elena National Cancer Institute, Rome,
Italy, between June 2004 and August 2006.
NSCLC was pathologically staged according to the
TNM (tumour-nodes-metastasis) classification (Union
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stage IB (n. 36); stage IIA (n. 1); stage IIB (n. 23); stage
IIIA (n. 32); stage IIIB (n. 8); stage IV (n. 45). Most
patients with I to IIIA stages underwent surgery for
their primary tumours at the Thoracic Surgery Unit
of the Regina Elena National Cancer Institute, Rome,
Italy, while most patients with stages IIIB and IV had
chemotherapy. Radiotherapy was added if necessary.
NSCLC grade was expressed as G parameter, univer-
sally accepted as a pathological descriptor for cancer:
the more the tumour sections resemble the original nor-
mal tissue, when observed by pathologist, the lower
the grade, ranging from G1 (well differentiated) to G3
(poorly differentiated), being G2 an intermediated form
(moderately differentiated).
The study was approved by the Ethical Committee on
human experimentation of the promoting institution,
Regina Elena National Cancer Institute, Rome, Italy. All
participants in the study gave their written informed
consent. The lung cancer patients were followed until
October 2009.
Serum p53Ab assay
Serum samples were obtained from patients at the time
of diagnosis. All samples were aliquoted, coded, and
stored at −80°C until assays were performed. p53Abs
were detected by a commercially available, highly specific
ELISA kit (Anti-p53 ELISA II kit, PharmaCell, Paris,
France), using micro-titre plates coated either with human
recombinant p53 protein to detect specific p53Abs or with
control proteins to reveal non-specific interactions. The
assay was performed according to the manufacturer’s in-
structions. All samples were tested blindly, twice in the
same assay. Absorbance was measured at 450 nm and
620 nm, using a programmable ELISA reader. p53Ab
levels ≥1.2 units/ml were considered as positive, according
to the manufacturer’s suggestion; this cut-off was in agree-
ment with other studies [11]. p53Ab levels <1.2 units/ml
were considered as low/negative.Figure 1 Immunohistochemistry of p53 in a lung adenocarcinoma. A)
negative: no p53 nuclear staining. Magnification ×20.p53 protein expression
p53 immunostaining was performed by using the mono-
clonal antibody D07 (Novocastra, Menarini, Florence,
Italy). Immunoreactions were revealed by a streptavidin-
biotin enhanced immunoperoxidase technique (Super
Sensitive MultiLink, Menarini) in an automated autostai-
ner (Vysion Biosystems Bond; Menarini, Florence, Italy).
Diaminobenzidine was used as the chromogenic sub-
strate. Tumour samples with >10% of tumour cells show-
ing positive nuclear staining were considered as positive
(Figure 1).
Genomic DNA extraction, PCR (Polymerase Chain
Reaction) amplification of the TP53 exons 2–11, and
mutational analysis by direct sequencing
DNA extraction from formalin-fixed paraffin-embedded
(FFPE) tissue samples on histological sections was per-
formed. For microdissection, appropriate tissue blocks
were selected and multiple serial sections were stained
with haematoxylin and eosin, and visualized with an
inverted microscope. Under an operating microscope,
tumour epithelium tissues were dissected from the cor-
responding unstained 10-μm sections by using a steril-
ized needle. These tissues were collected, deparaffinised
and digested with proteinase K overnight in lysis buffer,
before DNA isolation with the QIAamp DNA FFPE
Tissue Kit (QIAGEN, USA). DNA was eluted in a vol-
ume of 50–150 μl of water. DNA concentrations were
measured by Nanodrop and the amount of isolated
DNA ranged from 50–300 ng/μl. About 50–100 ng of
genomic DNA was used for eleven PCR reactions to
amplify the regions of the TP53 exons 2–11. Primers
were designed to amplify these DNA regions (Table 2).
All PCR reactions were in a volume of 20 μl containing
8 pmol of each primer, 0.20 mM each dNTP, 1-X of
Kapa Taq Buffer A with MgCl2, 0.25 units of Kapa Taq
(Kapa Biosystems, South Africa), and the appropriate
volume of H2O. Thermocycle PCR protocol was per-
formed as follows: 2 minutes at 95°C, 35–40 cycles atp53 positive: strong p53 immunoreactivity of the nuclei. B) p53
Table 2 Primers for TP53 exon 2–11 amplification and
sequencing analysis
TP53 exon 2 Fw 5′ GGTTGGAAGTGTCTCATGC 3′
Rv 5′ TTCGCTTCCCACAGGTCTC 3′*
TP53 exon 3 Fw 5′ AGAGACCTGTGGGAAGCGA 3′*
Rv 5′ GCAGTCAGAGGACCAGGT 3′
TP53 exon 4a Fw 5′ TGGTCCTCTGACTGCTCTT 3′
Rv 5′ AAGAAGCCCAGACGGAAACC 3′*
TP53 exon 4b Fw 5′ AGCTCCCAGAATGCCAGAG 3′*
Rv 5′ CAGGCATTGAAGTCTCATGG 3′
TP53 exon 5 Fw 5′GCCCTGACTTTCAACTCTG 3′
Rv 5′ GGCAACCAGCCCTGTCGT 3′*
TP53 exon 6 Fw 5′ CAGGCCTCTGATTCCTCAC 3′
Rv 5′ CTACTGCTCACCTGGAGG 3′*
TP53 exon 7 Fw 5′ CTTGGGCCTGTGTTATCTC 3′
Rv 5′AAATCGGTAAGAGGTGGGC 3′*
TP53 exon 8 Fw 5′ ACAAGGGTGGTTGGGAGTAG 3′*
Rv 5′ CCTCCACCGCTTCTTGTCC 3′
TP53 exon 9 Fw 5′CAAGAAGCGGTGGAGGAGA 3′*
Rv 5′ TCCACTTGATAAGAGGTCCCA 3′
TP53 exon 10 Fw 5′ CCATCTTTTAACTCAGGTACTG 3′
Rv 5′TGAAGGCAGGATGAGAATGG 3′*
TP53 exon 11 Fw 5′CACAGACCCTCTCACTCAT 3′
Rv 5′TCCTGGGTGCTTCTGACG 3′*
*Primers used for sequencing; Fw, forward; Rv, reverse.
Table 3 Serum p53Abs in lung cancer patients and






Lung cancer sera 201 41a (20.4%) 160a (79.6%)
Control sera 54 0a 54a
Lung cancer tissues 131 75b (57.3%) 56b (42.7%)
ap53Ab, bp53 protein expression.
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30 seconds, followed by 72°C for 2 minutes. PCR ampli-
cons obtained from DNA were purified by gel filtration
with Sephadex G-100 (GE Healthcare, USA). About 15–
30 ng of PCR products were sequenced directly by
using the Big Dye V3.1 Cycle-Sequencing kit (Applied
Biosystems, USA) with proper primers (Table 2). After se-
quencing reaction, the entire reactions of every mixture
were purified by gel filtration with Sephadex G-50 (GE
Healthcare, USA) and analyzed by 3730 DNA Analyzer
(Applied Biosystems, USA).
Statistical analysis
All statistical analyses were performed by using R [12].
For all measured endpoints, all times were calculated
after primary diagnosis of lung cancer and patients were
censored at the time of the specific event. Actuarial
curves of the length of time until the death were calcu-
lated by the Kaplan and Meier product-limit method.
The comparison of the actuarial curves was evaluated by
the log-rank test. Tests for statistical significance were
performed with the chi-square and t-test for categorical
and continuous variables, respectively. Multivariate ana-
lysis of prognostic factors was performed using the Cox
proportional hazard model. In both univariate andmultivariate analysis, p-values of <0.05 were considered
statistically significant.
Results
Serum p53Abs in lung cancer patients
Sera from 201 patients with primary lung carcinoma
were evaluated for the presence of p53Abs using a highly
specific ELISA kit. Our results demonstrated that 20.4%
of lung cancer patients (41 out of 201) had positive
levels of serum p53Abs, while none of the 54 controls
resulted positive (Table 3). Our results agree with data
from other studies on lung carcinoma where the fre-
quency of p53Abs in serum ranged from 18.8% to 32.1%
of the patients [13,14]. In particular, 36 out of 188
NSCLC patients (19.1%) and 5 out of 13 SCLC patients
(38.5%) were positive for serum p53Abs.
Serum p53Abs and p53 tumour expression
High levels of p53 tumour expression were demon-
strated in 75 out of 131 lung cancer patients (57.3%),
for whom tumour tissues were available (Table 3).
Among these patients, 19 (16 NSCLC and 3 SCLC)
out of 22 positive for serum p53Abs resulted also posi-
tive for p53 tumour overexpression (86.4%), while 56
(53 NSCLC and 3 SCLC) out of 109 low/negative for
serum p53Abs were positive for p53 tumour overex-
pression (51.4%). A significant correlation (p = 0.005)
between positive levels of circulating p53Abs and high
levels of p53 expression in the corresponding tumours
was observed (Table 4).
Serum p53Abs, p53 tumour expression and
clinicopathologic parameters
The relationships among levels of p53Abs or p53 accu-
mulation and clinical or tumour biological parameters of
lung cancer patients were evaluated. No difference was
found with regard to age and sex. By histological types,
positive levels of p53Abs were more frequently found in
patients with squamous cell carcinoma than adenocar-
cinoma (p = 0.068), while the numbers of other sub-
groups were too few to draw meaningful conclusions
(Table 5). In NSCLC, there was a difference of border-
line significance (p = 0.054) in the incidence of p53Abs
between stage I and the more advanced stages II-IV.
Table 4 Relationship between serum p53Abs and p53
tumour staining in lung cancer patients
p53 tumour
staining
No. of p53Ab-positive No. of p53Ab-
low/negative
p-value
Positive 19 (86.4%) 56 (51.4%) 0.005
Negative 3 (13.6%) 53 (48.6%)
Table 6 Relationship between p53 overexpression and
clinicopathologic parameters
No. of cases No. of patients with
p53 overexpression
Age (years)
≤60 27 16 (59.3%)
>60 104 59 (56.7%)
Total 131 75 (57.3%)
Sex
Male 101 57 (56.4%)
Female 30 18 (60.0%)
Total 131 75 (57.3%)
Histological type
NSCLC
Adenocarcinoma 59 26 (44.1%)
Squamous cell carcinoma 46 33 (71.7%)
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cantly correlated with tumours showing poorly differ-
entiated grade (p = 0.016). Furthermore, a significant
correlation between high levels of p53 protein expression
and squamous cell carcinoma compared to adenocarcin-
oma was observed (p = 0.008), while no difference was
found with regard to NSCLC stage (Table 6); p53 overex-
pression was also significantly associated with NSCLC of
highest grade (p = 0.012).Table 5 Correlation between serum p53Abs and
clinicopathologic features
No. of cases No. of p53Ab-positive
Age (years)
≤60 47 11 (23.4%)
>60 154 30 (19.5%)
Sex
Male 157 29 (18.5%)
Female 44 12 (27.3%)
Histological type
NSCLC
Adenocarcinoma 79 10 (12.7%)
Squamous cell carcinoma 70 18 (25.7%)
Bronchioloalveolar carcinoma 6 0 (0%)
Large cell carcinoma 5 1 (20.0%)
Anaplastic carcinoma 19 5 (26.3%)
Mixed carcinoma 9 2 (22.2%)
SCLC 13 5 (38.5%)
NSCLC stage
I 68 7 (10.3%)
II 24 7 (29.2%)
III 40 9 (22.5%)
IV 45 9 (20.0%)
Missing 11 4 (36.4%)
Total 188 36 (19.1%)
II-IV 109 25 (22.9%)
NSCLC grade
G1 4 0 (0%)
G2 57 4 (7.0%)
G3 72 18 (25.0%)
Missing 55 14 (25.5%)
Total 188 36 (19.1%)
Bronchioloalveolar carcinoma 5 1 (20.0%)
Large cell carcinoma 4 4 (100%)
Anaplastic carcinoma 4 4 (100%)
Mixed carcinoma 5 1 (20.0%)
SCLC 8 6 (75.0%)
Total 131 75 (57.3%)
NSCLC stage
I 62 35 (56.4%)
II 17 9 (52.9%)
III 22 15 (68.2%)
IV 18 8 (44.4%)
Missing 4 2 (50.0%)
Total 123 69 (56.1%)
NSCLC grade
G1 3 1 (33.3%)
G2 53 21 (39.6%)
G3 60 40 (66.7%)
Missing 7 7 (100%)
Total 123 69 (56.1%)TP53 gene mutations and clinicopathologic features
From the 75 tumours positively staining for p53 protein,
only 53 had enough tumour tissue to be investigated for
TP53 gene mutations in exons 2–11. Of these 53 tumour
samples, 13 (all NSCLC, 24.5%) showed TP53 mutations
(9 missense mutations and 4 deletions), while 40 (39
NSCLC and 1 SCLC, 75.5%) showed no mutation; the
median rate of tumour cells with p53 overexpression in
tumours with mutations was 60%, while in tumours with-
out mutations was 40% (p = 0.04). Mutational analysis was
also performed in 12 patients without p53 protein overex-
pression by IHC (all NSCLC), whose DNA was available
for direct sequencing; in this group, compatible with p53
negative staining, we found 9 patients with wild-type p53
and 3 patients with p53 deletions (Figure 2).
Figure 2 Overlap between p53Ab-positivity, p53 expression and TP53 mutation in lung cancer patients (n = 65). * Percentage of tumour
cells showing p53 staining.
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followed by exon 8 (5/16), exon 4 and exon 2 (2/16); only
one mutation was found in exon 6 (Table 7). Of the 16 mu-
tations, 9 (56.2%) were missense mutations and 7 (43.7%)
were deletions; 5 out of 9 point mutations (55.6%) were
base pair transversions (G = > T 4/9, G = > C 1/9),
while 4 (44.4%) were transitions (C = > T). The same
mutation p.Pro12Leu was found in exon 2 in two pa-
tients; according to both the IARC (International
Agency for Research on Cancer) TP53 mutational data-
base and UMD (Universal Mutation Database) TP53
mutation database, this mutation is functional in yeast
but extremely rare. Thus, to verify its presence in two
different patients, we performed two independent DNA
purifications, PCR reactions, and direct sequences for
each biopsy. The results confirmed the presence of the
same mutation in the two patients, suggesting that its
rarity might be due, at least in part, to the fact that
many studies are limited to exons 5–9, where TP53
mutations are more frequent.
In our cohort, TP53 mutations were more frequently
associated with NSCLC of highest grade, although the
difference did not reach a statistical significance, likely
due to the small size of the sample. Other clinicopatho-
logic features, such as age and sex of patients, histo-
logical type of tumours and NSCLC stage were not
significantly correlated with TP53 mutations (Table 8).
Serum p53Abs and TP53 gene mutations
The corresponding sera of the 53 patients with tumours
positively staining for p53 protein, investigated for TP53
mutations, were available. Eleven of these patients (allTable 7 Details of lung cancer patients with TP53 mutations i
Patient number Sex Age Histology* TNM G§ p53Abs
8 M 70 SCC IB 3 N&
4 M 70 ADC IB 3 P
54 M 59 ADC IIB 3 N
1 M 72 SCC IA 3 N
55 M 77 SCC IA 3 N
10 F 55 SCC IIB 3 N
2 M 65 LCC IB 3 N
5 M 41 APC IIB 3 P
3 M 76 SCC IIB 3 N
7 M 73 SCC IB 2 N
11 F 68 ADC IB 2 N
56 M 70 ADC IA 2 N
6 F 82 ADC IIB 2 P
9 M 50 ADC IB 3 N
12 F 70 SCC IB 2 N
13 M 79 SCC IIB 3 N
*SCC, squamous cell carcinoma; ADC, adenocarcinoma; APC, anaplastic carcinoma; Lwith NSCLC) were positive for serum p53Abs (20.8%)
and three showed missense mutations in the corre-
sponding tumours (27.3%), while ten patients (all with
NSCLC) out of the 42 with low/negative-serum (41 with
NSCLC and 1 with SCLC) had missense mutations or
deletions in their tumours (23.8%). The sera of the 12
patients without p53 protein overexpression, whose
DNA was available for TP53 mutational analysis, were
all low/negative for serum p53Abs (Figure 2). In our lim-
ited cohort, there was not a statistically significant asso-
ciation between serum p53Abs and the presence of
TP53 mutations in the corresponding tumours.
Serum p53Abs and clinical outcome
We then considered the correlation between the pres-
ence of p53Abs in the serum and survival. The overall
survival time of patients with p53Ab-low/negative-serum
and NSCLC was significantly longer compared to
serum-positive patients (p = 0.049); the rates of survival
at 30 months were 54% versus 31% in patients with low/
negative or positive-serum, respectively (Figure 3). In
particular, patients with squamous cell carcinoma and
p53Ab-low/negative-serum showed a statistically signifi-
cant advantage in survival rate at 30 months compared
to serum-positive patients, 57% versus 18% respectively
(p = 0.044, Figure 4), while no difference was observed in
patients with adenocarcinoma (Figure 5); similarly, no
difference was found with regard to stage or grade. In
this study, there was no correlation between p53 overex-
pression or TP53 mutations in NSCLC and survival.
Multivariate analysis comprised age (as categorical,
>60 years), sex, histological type, stage, grade, and serumn their tumours
IHC Exon Codon Nucleic acid change Aminoacid change
P# 2 12 c.35C > T Pro12Leu
P 2 12 c.35C > T Pro12Leu
N 4 66-81 c.196_241del46 Frameshift
P 4 110 c.329G > T Arg110Leu
N 5 152 c.456delG Frameshift
P 5 154 c.460_474del15 Frameshift
P 5 157 c.469G > T Val157Phe
P 5 158 c.473G > T Arg158Leu
P 5 159 c.475G > C Ala159Pro
P 5 167 c.501G > T Gln167His
P 6 199-200 c.596_598delGAA Frameshift
N 8 269 c.807delC Frameshift
P 8 273 c.817C > T Arg273Cys
P 8 282 c.844C > T Arg282Trp
P 8 288 c.862delA Frameshift
P 8 288 c.862delA Frameshift
CC, large cell carcinoma. §Grade; &Low/Negative, #Positive.
Table 8 Comparison of TP53 mutations and
clinicopathologic features
No. of cases No. of patients with
TP53 mutations
Age (years)
≤60 12 4 (33.3%)
>60 53 12 (22.7%)
Total 65 16 (24.6%)
Sex
Male 51 12 (23.5%)
Female 14 4 (28.6%)
Total 65 16 (24.6%)
Histologic type
NSCLC
Adenocarcinoma 27 6 (22.2%)
Squamous cell carcinoma 27 8 (29.6%)
Bronchioloalveolar carcinoma 2 0 (0%)
Large cell carcinoma 4 1 (25.0%)
Anaplastic carcinoma 2 1 (50.0%)
Mixed carcinoma 2 0 (0%)
SCLC 1 0 (0%)
Total 65 16 (24.6%)
NSCLC stage
I 41 10 (24.4%)
II 9 6 (66.7%)
III 10 0 (0%)
IV 4 0 (0%)
Total 64 16 (25.0%)
NSCLC grade
G1-G2 28 5 (17.9%)
G3 35 11 (31.4%)
Missing 1 0 (0%)
Total 64 16 (25.0%)
Figure 3 Survival curves of NSCLC patients with p53Ab-positive
or p53Ab-low/negative- serum. Survival curves of NSCLC patients
with p53Ab-positive-serum (dotted line, n = 36) or p53Ab-low/
negative-serum (unbroken line, n = 152). Patients with p53Ab-low/
negative-serum had a significantly longer overall survival than those
with p53Ab-positive-serum (p = 0.049).
Figure 4 Survival curves of squamous cell carcinoma patients
with p53Ab-positive or p53Ab-low/negative-serum. Survival
curves of patients with squamous cell carcinoma of the lung with
p53Ab-positive-serum (dotted line, n = 18) or p53Ab-low/negative-serum
(unbroken line, n = 52). Patients with p53Ab-low/negative-serum
showed a significantly longer overall survival than those with
p53Ab-positive- serum (p = 0.044).
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factor (p < 0.001), while serum p53Abs resulted an inde-
pendent variable as a trend (p = 0.096).
Discussion
Our data showed that 20.4% of lung cancer patients had
positive levels of serum p53Abs, while none of the con-
trols showed positive levels of these antibodies. A signifi-
cant correlation between positive levels of p53Abs and
p53 overexpression in the corresponding tumours was
observed (p = 0.005), suggesting that the presence of
p53Abs is related to the accumulation of p53 protein
in the primary tumour. In NSCLC, positive levels of
p53Abs were associated with squamous cell carcinoma
rather than adenocarcinoma (p = 0.068), a different
frequency also previously reported [9]. In our study,p53Abs were correlated with II-IV stages compared
to I stage (p = 0.054); similarly, the incidence of
p53Abs was previously found higher in lung cancer
patients with advanced stages III-IV compared to pa-
tients with early stages I-II [9]. We observed that the
Figure 5 Survival curves of adenocarcinoma patients with
p53Ab-positive or p53Ab-low/negative-serum. Survival curves of
patients with adenocarcinoma of the lung with p53Ab-positive-serum
(dotted line, n = 10) or p53Ab-low/negative-serum (unbroken line,
n = 69). No difference in overall survival was observed between the
two groups (p = 0.973).
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mours with poorly differentiated grade (p = 0.016). In
NSCLC, p53 overexpression significantly correlated
with squamous cell carcinoma compared to adenocarcin-
oma (p = 0.008) and with tumours showing highest grade
(p = 0.012). In previous studies, a statistically significant
correlation between p53 overexpression and squamous
cell carcinoma compared to adenocarcinoma was also
reported and, in particular, Rybarova et al. found a correl-
ation between p53 overexpression and poorly differenti-
ated tumours in NSCLC [15,16]. Finally, we did not find
a significant correlation between positive levels of serum
p53Abs and TP53 mutations in the corresponding tu-
mours, nor between TP53 mutations and clinicopatho-
logic features, presumably due to the small number of
suitable tumour samples, while a significant correlation
between TP53 mutations and tumours with the highest
median rate of p53 overexpression was observed within
the p53 protein-positive tumour samples (p = 0.04). In
particular, TP53 mutations were found in three out of 12
p53 protein-negative samples; the absence of p53 protein
expression in these samples may be due to the type of
mutations, as they were frameshift mutations. On the
other hand, four samples with frameshift mutations
showed p53 protein overexpression; in these samples,
overexpression of wild-type p53 protein might be attrib-
uted to inhibition of MDM2 (Mouse Double Minute 2
homolog)-mediated degradation of p53 or activation
of p14ARF (Alternate Reading Frame protein14), sincep14ARF binds to MDM2, thus preventing MDM2 bind-
ing to p53 and subsequent p53 degradation [17].
In the present study, survival time of NSCLC pa-
tients low/negative for serum p53Abs was significantly
longer than in positive patients (p = 0.049); moreover,
patients with squamous cell carcinoma low/negative
for serum p53Abs showed a significant increase in sur-
vival rate compared to positive patients (p = 0.044).
Our results are in agreement with other studies, in
which the presence of serum p53Abs has been associ-
ated with a poor prognosis. In a study by Mack et al.,
serum p53Abs were significantly correlated with a
poor survival in NSCLC patients [18]. Laudanski et al.
also showed a significant association between serum
p53Abs and poor survival in NSCLC patients, even
though in a multivariate analysis only the presence of
TP53 mutations remained an independent, significant
unfavourable prognostic factor for survival [15]. Bergqvist
et al., in a study regarding patients with advanced NSCLC,
reported a significant poor survival in patients positive
for serum p53Abs with adenocarcinoma, but not in
positive patients with squamous cell carcinoma [19].
Recently, Hashim et al. found that in NSCLC the
levels of serum p53Abs were significantly higher in
stage IV compared to stages I-III [20]. However, some
groups found no correlation with survival, while others
showed a longer survival in lung cancer patients posi-
tive for serum p53Abs compared to negative patients,
even though the difference did not reach a statistical
significance [21,22].
The mechanisms for the relationship between serum
p53Abs and prognosis are unclear. Usually, these anti-
bodies are considered as markers of TP53 mutations or
p53 overexpression in tumours, thus reflecting a poor
prognosis; however, the presence of serum p53Abs with
a T-cell response may have a favourable impact on sur-
vival by destructing tumour cells expressing a dysfunc-
tional p53. Serum p53Abs have been reported to be
directed against both mutant and wild-type p53 proteins,
where they recognize specific epitopes in the amino and
carboxyl-termini, and the antigenic load due to p53
overexpression triggers the development of these anti-
bodies [23]. However, only 20-40% of cancer patients
with TP53 mutations show circulating p53Abs, suggest-
ing that other biological characteristics may be involved
in this response, such as specific combination of Major
Histocompatibility Complex classes I and II molecules
expressed by each patient [3]. These observations may in
part explain the reported differences in prognostic corre-
lations of serum p53Abs.
Finally, in our study we did not find any significant
correlation between p53 overexpression or TP53 muta-
tions and survival in NSCLC, likely because of the re-
duced number of suitable tumour samples compared to
Mattioni et al. BMC Cancer  (2015) 15:148 Page 10 of 11serum samples. In some studies, p53 accumulation and
TP53 mutations have been reported as markers of poor
survival in NSCLC. Laudanski et al. showed that TP53
mutations and p53 overexpression were significantly cor-
related with poor survival in NSCLC; however, in a
multivariate analysis, only the presence of TP53 muta-
tions remained an independent, significant unfavourable
prognostic factor for survival [15]. Tsao et al. found that
patients with NSCLC overexpressing p53 showed sig-
nificant shorter survival compared to patients with
p53-negative tumours, while TP53 mutations were not
prognostic for survival [24]. However, other groups re-
ported no correlation between p53 accumulation and
survival in NSCLC or a not clear role for TP53 mutations
as a prognostic marker for survival in NSCLC [25,26].
Conclusions
In our investigation the presence of serum p53Abs, but
not p53 tumour overexpression or TP53 mutations,
identifies subsets of NSCLC patients with a shorter sur-
vival. Furthermore, positive levels of p53Abs were sig-
nificantly correlated with p53 overexpression in the
corresponding tumours, suggesting that the production
of these antibodies may be related to the accumulation
of p53 protein in the primary tumour. We were unable
to find any significant correlation between positive levels
of serum p53Abs and TP53 mutations in the corre-
sponding tumours.
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